Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626686 | 0.78 | GAA (0.35) | KDM4ERAB9AGAACDC7DBF4 | |
| SCHEMBL29877075 | 0.76 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL241856 | 0.76 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL20894398 | 0.74 | ALDH1A1 (0.36) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL18059154 | 0.74 | ALDH1A1 (0.32) | ALDH1A1HPGDTSHRGPR35PTPN1 | |
| SCHEMBL16346305 | 0.74 | GPR35 (0.42) | ALDH1A1HPGDTSHRGPR35SMN1; SMN2 | |
| SCHEMBL14036968 | 0.73 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4ERAB9ANPC1 | |
| SCHEMBL18173828 | 0.73 | GPR35 (0.42) | ALDH1A1HPGDTSHRGPR35POLB | |
| SCHEMBL13534398 | 0.73 | ALDH1A1 (0.41) | ALDH1A1HPGDSMN1; SMN2KDM4ERAB9A | |
| SCHEMBL622999 | 0.73 | HSD17B10 (0.47) | ALDH1A1HPGDTSHRKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| CN-120136863-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-120025327-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025328-A | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-05-23 | — | — | CN | disclosed |
| EP-4532485-A1 | TYK2 INHIBITORS AND USES THEREOF | Sudo Biosciences Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025068514-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2025-04-03 | — | — | WO | disclosed |
| CN-114929694-B | Adrenergic receptor ADRAC2 antagonists | 拜耳公司 | 2025-02-07 | — | — | CN | disclosed |
| WO-2024199524-A1 | COMPOUND AS PKMYT1 INHIBITOR | 江苏星盛新辉医药有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-20240189309-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2024-06-13 | — | — | US | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-7323482-B2 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-29 | — | — | US | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096315-A1 | 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACIDS AND 4-PHENYL-THIAZOLE-5-CARBOXYLIC ACID AMIDES AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | BOYLAN JOHN FREDERICK | 2007-08-30 | — | — | US | disclosed |
| US-20070093537-A1 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093537-A1 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-7169771-B2 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169771-B2 | Thiazolyl-based compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189309-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4745/4885HPGD 4028/4885TSHR 2031/4885 |
| US-20070203210-A1 | Thiazolyl-benzimidazoles | CYP3A7, CYP2C19, CYP3A5 | ALDH1A1 100/4885HPGD 1891/4885TSHR 876/4885 |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | ALDH1A1 680/4885HPGD 3134/4885TSHR 2427/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | ALDH1A1 2100/4885HPGD 3170/4885TSHR 613/4885 |
| US-20070093537-A1 | Thiazolyl-based compounds useful as kinase inhibitors | MAP3K1, MAPK1, MAP3K5 | ALDH1A1 1540/4885HPGD 1677/4885TSHR 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.